Merrill Lynch Keeps a Sell Rating on Seattle Genetics (SGEN)
In a report released yesterday, Tazeen Ahmad from Merrill Lynch reiterated a Sell rating on Seattle Genetics (SGEN), with a price target of $83.00. The company’s shares closed last Monday at $98.64, close to its 52-week high of $102.84.
According to TipRanks.com, Ahmad is a 4-star analyst with an average return of 10.6% and a 41.2% success rate. Ahmad covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals Inc, Fulcrum Therapeutics Inc, and Adamas Pharmaceuticals.
Seattle Genetics has an analyst consensus of Moderate Buy, with a price target consensus of $101.83.
See today’s analyst top recommended stocks >>
The company has a one-year high of $102.84 and a one-year low of $50.71. Currently, Seattle Genetics has an average volume of 981K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Seattle Genetics, Inc. is a biotechnology company, which engages in the development and commercialization of antibody-based therapies for the treatment of cancer. Its product Adcetris is an antibody-drug for the treatment of lymphoma. The firm is also advancing a pipeline of novel therapies for solid tumors and blood-related cancers.
Read More on SGEN: